Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

Clinical trial NCT01869114 · COMPLETED

Trial details

NCT number: NCT01869114
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)de Novo Myelodysplastic Syndromes Myelodysplastic Syndrome With Isolated Del(5q)Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Myeloid Leukemia

Start date: 2013-07-08
Primary completion: 2024-01-03
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.